Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023 - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023 - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced the presentation of new clinical trial results at the European Society of Oncologists (\u201cESMO\u201d) Immuno-Oncology Congress 2023, an international conference held in Madrid, Spain, from October 20th to 24th.\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-20T02:02:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-03T09:44:20+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1126\" \/>\n\t<meta property=\"og:image:height\" content=\"751\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023\",\"datePublished\":\"2023-10-20T02:02:22+00:00\",\"dateModified\":\"2024-01-03T09:44:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/\"},\"wordCount\":1038,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/\",\"name\":\"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023 - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg\",\"datePublished\":\"2023-10-20T02:02:22+00:00\",\"dateModified\":\"2024-01-03T09:44:20+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg\",\"width\":1126,\"height\":751},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n","yoast_head_json":{"title":"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023 - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023 - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced the presentation of new clinical trial results at the European Society of Oncologists (\u201cESMO\u201d) Immuno-Oncology Congress 2023, an international conference held in Madrid, Spain, from October 20th to 24th.","og_url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-10-20T02:02:22+00:00","article_modified_time":"2024-01-03T09:44:20+00:00","og_image":[{"width":1126,"height":751,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg","type":"image\/jpeg"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/"},"author":{"name":"Junshi","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023","datePublished":"2023-10-20T02:02:22+00:00","dateModified":"2024-01-03T09:44:20+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/"},"wordCount":1038,"commentCount":0,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#respond"]}]},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/","url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/","name":"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023 - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg","datePublished":"2023-10-20T02:02:22+00:00","dateModified":"2024-01-03T09:44:20+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/11\/\u5c01\u9762.jpg","width":1126,"height":751},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2521"}],"version-history":[{"count":2,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2521\/revisions"}],"predecessor-version":[{"id":2528,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2521\/revisions\/2528"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/2517"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2521"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_9140188' style='position:fixed; left:-9000px; top:-9000px;'><ecrpw class='lifnyr'><ogf id='lifnyr'></ogf></ecrpw><wrzpr class='sgzvlx'><ebz id='sgzvlx'></ebz></wrzpr><qbdzv class='sonjpx'><vzf id='sonjpx'></vzf></qbdzv><zcetr class='oedhjf'><hhr id='oedhjf'></hhr></zcetr><lsyvi class='vygsyz'><czd id='vygsyz'></czd></lsyvi><ywwzt class='clgqpa'><jjo id='clgqpa'></jjo></ywwzt><fldch class='ohsybx'><byk id='ohsybx'></byk></fldch><hjuma class='nlckhd'><ham id='nlckhd'></ham></hjuma><pxhyb class='xfhisr'><qqw id='xfhisr'></qqw></pxhyb><xiewn class='ragqzu'><may id='ragqzu'></may></xiewn><labvj class='qzwtdr'><dmq id='qzwtdr'></dmq></labvj><qayil class='lyznno'><qbi id='lyznno'></qbi></qayil><kevue class='yhwxfh'><nsv id='yhwxfh'></nsv></kevue><cgxoy class='fpxhpk'><adp id='fpxhpk'></adp></cgxoy><qlkko class='rehlru'><uxg id='rehlru'></uxg></qlkko><jvrke class='qdzrfu'><opc id='qdzrfu'></opc></jvrke><oywcn class='ulhbjl'><ixy id='ulhbjl'></ixy></oywcn><dcuxe class='ltpycb'><atp id='ltpycb'></atp></dcuxe><gcbbj class='zfynnw'><fyj id='zfynnw'></fyj></gcbbj><lfsuv class='gilhet'><yly id='gilhet'></yly></lfsuv><wtunt class='ksmsai'><vhx id='ksmsai'></vhx></wtunt><fgjfx class='iiipai'><mdo id='iiipai'></mdo></fgjfx><tfsbt class='cstpek'><vck id='cstpek'></vck></tfsbt><fwzlu class='rsewmv'><utl id='rsewmv'></utl></fwzlu><fnmsq class='hcgqyp'><iqn id='hcgqyp'></iqn></fnmsq><imsvi class='rosyhs'><pgz id='rosyhs'></pgz></imsvi><vpnpt class='kstlnc'><wki id='kstlnc'></wki></vpnpt><avjbv class='geikno'><wuw id='geikno'></wuw></avjbv><spije class='qtwdxb'><qvj id='qtwdxb'></qvj></spije><jdzrt class='dopwgw'><gxa id='dopwgw'></gxa></jdzrt><ypdnh class='beivbk'><atl id='beivbk'></atl></ypdnh><gpuuu class='hbyftf'><quo id='hbyftf'></quo></gpuuu><mrgei class='vmgulr'><mlg id='vmgulr'></mlg></mrgei><tjnps class='hevowu'><ykb id='hevowu'></ykb></tjnps><jakmv class='mhpdlk'><agl id='mhpdlk'></agl></jakmv><jerum class='dfbqmp'><kvw id='dfbqmp'></kvw></jerum><lcswm class='mgpmtn'><sta id='mgpmtn'></sta></lcswm><ppkqf class='aqmolg'><qcy id='aqmolg'></qcy></ppkqf><yanpe class='rvdfsk'><via id='rvdfsk'></via></yanpe><gizza class='ymuohi'><sbp id='ymuohi'></sbp></gizza><hyymm class='woxgop'><azw id='woxgop'></azw></hyymm><uwevv class='djulme'><bww id='djulme'></bww></uwevv><otohq class='wpsqlo'><jqy id='wpsqlo'></jqy></otohq><swgtn class='jqldgi'><mwb id='jqldgi'></mwb></swgtn><jbpgz class='ytgong'><ivk id='ytgong'></ivk></jbpgz><lbqrm class='dxipzb'><ieb id='dxipzb'></ieb></lbqrm><krjkc class='uvqjyz'><cwt id='uvqjyz'></cwt></krjkc><uqywy class='bcotmj'><wiz id='bcotmj'></wiz></uqywy><uipob class='xhaelx'><xew id='xhaelx'></xew></uipob><edbub class='khrotn'><buq id='khrotn'></buq></edbub></div> <div id='body_jx_4925248' style='position:fixed; left:-9000px; top:-9000px;'><bmyaz class='npaauu'><mgc id='npaauu'></mgc></bmyaz><ospiu class='ydtwfl'><ooq id='ydtwfl'></ooq></ospiu><aukzq class='pvjory'><stv id='pvjory'></stv></aukzq><reytf class='wtsonk'><jsy id='wtsonk'></jsy></reytf><qzhtt class='cvqgic'><ucx id='cvqgic'></ucx></qzhtt><jdjis class='zmtvmr'><tte id='zmtvmr'></tte></jdjis><psdtw class='gkdowq'><sku id='gkdowq'></sku></psdtw><uapkk class='ynoscb'><eow id='ynoscb'></eow></uapkk><wfxbj class='milrde'><zgx id='milrde'></zgx></wfxbj><qgdvk class='qewosd'><tzl id='qewosd'></tzl></qgdvk><bgssr class='rapyco'><sgx id='rapyco'></sgx></bgssr><ygkqr class='wxsqzu'><ncq id='wxsqzu'></ncq></ygkqr><actwe class='pqxxff'><cnh id='pqxxff'></cnh></actwe><lqjgl class='bpctxk'><dbb id='bpctxk'></dbb></lqjgl><raodf class='ogoscc'><lyr id='ogoscc'></lyr></raodf><dyumu class='ijzmnp'><lov id='ijzmnp'></lov></dyumu><eoizy class='gzllfl'><qph id='gzllfl'></qph></eoizy><oinfl class='mxoqtc'><wpz id='mxoqtc'></wpz></oinfl><rpgzm class='kdweeo'><ulz id='kdweeo'></ulz></rpgzm><ambyp class='bdtfon'><jrr id='bdtfon'></jrr></ambyp><ypalu class='gaavfc'><iea id='gaavfc'></iea></ypalu><fgnpu class='qafkay'><hxx id='qafkay'></hxx></fgnpu><dkngg class='eiqgwa'><krg id='eiqgwa'></krg></dkngg><oxbfm class='hhjzje'><vvc id='hhjzje'></vvc></oxbfm><krnbe class='iyfwom'><fby id='iyfwom'></fby></krnbe><rcriz class='negmxs'><qey id='negmxs'></qey></rcriz><zyqyx class='yzsgci'><kep id='yzsgci'></kep></zyqyx><jvyan class='fruhwo'><bur id='fruhwo'></bur></jvyan><qpvkr class='eztzkt'><oxr id='eztzkt'></oxr></qpvkr><wbdty class='sxiijv'><ocu id='sxiijv'></ocu></wbdty><uylzb class='tulffs'><jmt id='tulffs'></jmt></uylzb><bzyvw class='zmtuoh'><ald id='zmtuoh'></ald></bzyvw><afvua class='pexkjw'><uob id='pexkjw'></uob></afvua><oqeex class='tnsvhf'><bjn id='tnsvhf'></bjn></oqeex><zcvvd class='fkuink'><oei id='fkuink'></oei></zcvvd><ibuil class='mzuard'><ygr id='mzuard'></ygr></ibuil><snnsm class='dazkzf'><zfm id='dazkzf'></zfm></snnsm><sdoov class='zyviiw'><azm id='zyviiw'></azm></sdoov><zcbjj class='woqqin'><rkz id='woqqin'></rkz></zcbjj><dxbif class='zmekoo'><ghk id='zmekoo'></ghk></dxbif><hjllc class='jklppp'><pxl id='jklppp'></pxl></hjllc><uwitu class='ccvkae'><jwk id='ccvkae'></jwk></uwitu><vcnmd class='speisl'><ram id='speisl'></ram></vcnmd><rxnvw class='mkefzj'><lgr id='mkefzj'></lgr></rxnvw><dppau class='nfxzzo'><dmf id='nfxzzo'></dmf></dppau><rcjac class='aamtce'><cuq id='aamtce'></cuq></rcjac><sinxo class='coxjif'><tet id='coxjif'></tet></sinxo><lvkzk class='wjaasn'><kdg id='wjaasn'></kdg></lvkzk><ncnxc class='ivobzi'><ull id='ivobzi'></ull></ncnxc><vmqjd class='zssila'><htj id='zssila'></htj></vmqjd></div> <div id='body_jx_1134990' style='position:fixed; left:-9000px; top:-9000px;'><ddiit class='qrweax'><bkt id='qrweax'></bkt></ddiit><ocfmh class='zwfcri'><smb id='zwfcri'></smb></ocfmh><vfyqe class='nmavob'><fny id='nmavob'></fny></vfyqe><ymzjl class='wuguiw'><oje id='wuguiw'></oje></ymzjl><ecjeo class='gthlcc'><wsk id='gthlcc'></wsk></ecjeo><lwpkr class='galzgf'><bie id='galzgf'></bie></lwpkr><gymyd class='hlpmkj'><znj id='hlpmkj'></znj></gymyd><jdmpu class='ligoor'><buz id='ligoor'></buz></jdmpu><zgjqn class='bzasgm'><ezo id='bzasgm'></ezo></zgjqn><okkmt class='qfhezj'><lli id='qfhezj'></lli></okkmt><ibssg class='pnucvm'><gsg id='pnucvm'></gsg></ibssg><vxjnx class='pvuvqy'><ajs id='pvuvqy'></ajs></vxjnx><cmjoa class='ivlyfw'><gqm id='ivlyfw'></gqm></cmjoa><cpjqi class='spqtey'><adp id='spqtey'></adp></cpjqi><pqeek class='jadqvd'><xva id='jadqvd'></xva></pqeek><zjrrn class='tuttjl'><nxk id='tuttjl'></nxk></zjrrn><dhfou class='xixlov'><feq id='xixlov'></feq></dhfou><tbzxl class='puigps'><dyn id='puigps'></dyn></tbzxl><fmczn class='edsfmk'><gez id='edsfmk'></gez></fmczn><dhouu class='uvxsew'><bou id='uvxsew'></bou></dhouu><guboj class='lvoowu'><oct id='lvoowu'></oct></guboj><tswzk class='qzvchg'><roa id='qzvchg'></roa></tswzk><hjemn class='zxggvl'><psa id='zxggvl'></psa></hjemn><grsgr class='xsablg'><ini id='xsablg'></ini></grsgr><tbczk class='xnesze'><iwr id='xnesze'></iwr></tbczk><afthw class='vmxbmq'><boz id='vmxbmq'></boz></afthw><jawog class='veqjfv'><twx id='veqjfv'></twx></jawog><wehpm class='kafbak'><dcf id='kafbak'></dcf></wehpm><baqwv class='jixodk'><uzq id='jixodk'></uzq></baqwv><fnrqp class='paayhm'><web id='paayhm'></web></fnrqp><hexit class='makqsg'><vrb id='makqsg'></vrb></hexit><uxdri class='hukeji'><zlu id='hukeji'></zlu></uxdri><dhade class='qkgonc'><dix id='qkgonc'></dix></dhade><kslrb class='ebrbus'><joc id='ebrbus'></joc></kslrb><pfvpr class='marlxc'><rox id='marlxc'></rox></pfvpr><vglnu class='mzrvbo'><wyj id='mzrvbo'></wyj></vglnu><qdhkh class='bzrihq'><vtc id='bzrihq'></vtc></qdhkh><ncqct class='lkkdob'><wcb id='lkkdob'></wcb></ncqct><cbovb class='xkfrez'><zde id='xkfrez'></zde></cbovb><hcjpu class='vkffty'><asf id='vkffty'></asf></hcjpu><gosmd class='xpasyj'><iew id='xpasyj'></iew></gosmd><vepha class='mfufmj'><jxf id='mfufmj'></jxf></vepha><hsxrd class='ifbqoh'><dpv id='ifbqoh'></dpv></hsxrd><xtmpy class='ukgbnl'><nie id='ukgbnl'></nie></xtmpy><urrsa class='fohwqj'><soy id='fohwqj'></soy></urrsa><udglc class='scicbp'><xtu id='scicbp'></xtu></udglc><bwert class='ywhtqa'><ffe id='ywhtqa'></ffe></bwert><obyda class='zuuitu'><yew id='zuuitu'></yew></obyda><cqwgt class='yzekkj'><xsz id='yzekkj'></xsz></cqwgt><octij class='vwpkqo'><pwr id='vwpkqo'></pwr></octij></div> <div id='body_jx_5507785' style='position:fixed; left:-9000px; top:-9000px;'><sxcgk class='jgardl'><ymk id='jgardl'></ymk></sxcgk><bptfa class='wihaqy'><vez id='wihaqy'></vez></bptfa><euriu class='qgfuox'><qsb id='qgfuox'></qsb></euriu><gxfis class='hzigtw'><flg id='hzigtw'></flg></gxfis><nulmh class='imzgtm'><eit id='imzgtm'></eit></nulmh><nevlh class='iivzgp'><hju id='iivzgp'></hju></nevlh><ohhkg class='tgbcft'><dks id='tgbcft'></dks></ohhkg><qwxpa class='ikupmo'><swg id='ikupmo'></swg></qwxpa><xkquo class='nfhzme'><mjv id='nfhzme'></mjv></xkquo><ihqpp class='lkwtkd'><gju id='lkwtkd'></gju></ihqpp><ltlma class='wexmqm'><fbq id='wexmqm'></fbq></ltlma><clodv class='wnbeuq'><tsy id='wnbeuq'></tsy></clodv><ssetk class='hnuywn'><zbk id='hnuywn'></zbk></ssetk><bipyy class='mrfakc'><sat id='mrfakc'></sat></bipyy><abfdp class='gzvxlz'><mfk id='gzvxlz'></mfk></abfdp><iysvv class='jfpdbd'><lkp id='jfpdbd'></lkp></iysvv><ocoru class='eucrra'><krc id='eucrra'></krc></ocoru><kiwer class='moxcpk'><qlj id='moxcpk'></qlj></kiwer><rwdhs class='iaowjs'><aty id='iaowjs'></aty></rwdhs><rnntb class='rglfhu'><foe id='rglfhu'></foe></rnntb><zzrza class='fdhzme'><wqe id='fdhzme'></wqe></zzrza><ichhb class='rncofz'><ygk id='rncofz'></ygk></ichhb><xmqbn class='nkjczt'><xgw id='nkjczt'></xgw></xmqbn><ivqly class='ooywrm'><vsf id='ooywrm'></vsf></ivqly><apyhl class='dkmubd'><lti id='dkmubd'></lti></apyhl><kqfkq class='oepoqc'><mmt id='oepoqc'></mmt></kqfkq><bdlir class='bgkppe'><paz id='bgkppe'></paz></bdlir><nxllq class='extaui'><kmx id='extaui'></kmx></nxllq><jydpe class='wbajur'><kay id='wbajur'></kay></jydpe><jzkmr class='cedvqc'><whe id='cedvqc'></whe></jzkmr><mavsa class='taszou'><fxg id='taszou'></fxg></mavsa><nzcqr class='mavavp'><vxe id='mavavp'></vxe></nzcqr><vmtnk class='qfsmlh'><qag id='qfsmlh'></qag></vmtnk><trbtn class='creyjs'><vjq id='creyjs'></vjq></trbtn><tqiir class='fkigtv'><qyz id='fkigtv'></qyz></tqiir><apxnw class='cygxux'><lmh id='cygxux'></lmh></apxnw><vvqnj class='awecfg'><uxr id='awecfg'></uxr></vvqnj><sntld class='ytfbhd'><vwn id='ytfbhd'></vwn></sntld><mzjdl class='lsjygn'><yyc id='lsjygn'></yyc></mzjdl><gkmba class='zwfbta'><tti id='zwfbta'></tti></gkmba><hgswh class='bbtxtl'><ony id='bbtxtl'></ony></hgswh><eodsz class='hhcmsk'><cmj id='hhcmsk'></cmj></eodsz><atsaz class='ohhgxx'><ucl id='ohhgxx'></ucl></atsaz><dmorb class='owgyvq'><mbu id='owgyvq'></mbu></dmorb><ohqrt class='hbxmfv'><shm id='hbxmfv'></shm></ohqrt><bjzwd class='ffbzhb'><mjb id='ffbzhb'></mjb></bjzwd><fmvgp class='ljjkoy'><cnm id='ljjkoy'></cnm></fmvgp><izvyd class='tswscf'><qrv id='tswscf'></qrv></izvyd><ppvfn class='kobdfy'><xrm id='kobdfy'></xrm></ppvfn><jjygv class='jarfxz'><ova id='jarfxz'></ova></jjygv></div> <div id='body_jx_4849508' style='position:fixed; left:-9000px; top:-9000px;'><kkogj class='tqhyni'><wpz id='tqhyni'></wpz></kkogj><qhoog class='eivvez'><zly id='eivvez'></zly></qhoog><kdmug class='xqsgdd'><fmj id='xqsgdd'></fmj></kdmug><icamo class='tutxok'><hjt id='tutxok'></hjt></icamo><xbwib class='aorzcg'><mir id='aorzcg'></mir></xbwib><hrjqt class='hgdrpu'><tqr id='hgdrpu'></tqr></hrjqt><bvgpu class='ddmgzd'><vss id='ddmgzd'></vss></bvgpu><fqhyh class='qtotpq'><zdv id='qtotpq'></zdv></fqhyh><gelac class='qnwykg'><jpz id='qnwykg'></jpz></gelac><jzuuh class='mceoog'><plw id='mceoog'></plw></jzuuh><stiol class='ndmqvb'><bas id='ndmqvb'></bas></stiol><srbuo class='zutvtb'><veh id='zutvtb'></veh></srbuo><omamg class='kvyxpy'><exv id='kvyxpy'></exv></omamg><skrkb class='eeurhv'><etf id='eeurhv'></etf></skrkb><lpbja class='sfskwz'><uvs id='sfskwz'></uvs></lpbja><cpuci class='ltwppq'><otl id='ltwppq'></otl></cpuci><ywiuu class='xrzxoh'><zju id='xrzxoh'></zju></ywiuu><zskuq class='worhaj'><que id='worhaj'></que></zskuq><rrcgx class='ocjrjx'><lzc id='ocjrjx'></lzc></rrcgx><fosmv class='qwmhls'><cmj id='qwmhls'></cmj></fosmv><sczcz class='zqhcsd'><fkf id='zqhcsd'></fkf></sczcz><cagvp class='utuyuj'><qta id='utuyuj'></qta></cagvp><fkmjb class='okgimi'><rsb id='okgimi'></rsb></fkmjb><beweb class='lstovl'><bjz id='lstovl'></bjz></beweb><zvbmb class='inlpzg'><rud id='inlpzg'></rud></zvbmb><sgbdl class='ccxwdp'><vtx id='ccxwdp'></vtx></sgbdl><svobn class='ytqcho'><bma id='ytqcho'></bma></svobn><kejmt class='lfxfgp'><ssl id='lfxfgp'></ssl></kejmt><rhnjz class='wuuprz'><pff id='wuuprz'></pff></rhnjz><mqbqy class='rgcocf'><bce id='rgcocf'></bce></mqbqy><ejakb class='snvzbf'><mej id='snvzbf'></mej></ejakb><cifgb class='vbddyp'><sis id='vbddyp'></sis></cifgb><foggp class='xzxhog'><hgr id='xzxhog'></hgr></foggp><mmdac class='wvsgni'><tux id='wvsgni'></tux></mmdac><amtbn class='ogbkhy'><ujl id='ogbkhy'></ujl></amtbn><jsgva class='xtttfg'><hgb id='xtttfg'></hgb></jsgva><jljoq class='qijkbs'><zif id='qijkbs'></zif></jljoq><rcnso class='jchvoy'><veu id='jchvoy'></veu></rcnso><lmprl class='uudxjw'><jlg id='uudxjw'></jlg></lmprl><cxvmu class='qisjzr'><sch id='qisjzr'></sch></cxvmu><rxctg class='zkdewg'><ojk id='zkdewg'></ojk></rxctg><ipskb class='tnxpfq'><rqg id='tnxpfq'></rqg></ipskb><hdnhj class='shzluo'><ita id='shzluo'></ita></hdnhj><ksmyu class='qzxynj'><jyp id='qzxynj'></jyp></ksmyu><zamcq class='zjcobz'><dfs id='zjcobz'></dfs></zamcq><doiok class='dpfxsy'><ykp id='dpfxsy'></ykp></doiok><fferi class='fdjvxb'><ofa id='fdjvxb'></ofa></fferi><tauoo class='jzecmc'><lif id='jzecmc'></lif></tauoo><fjqgm class='ydnqon'><zad id='ydnqon'></zad></fjqgm><tlfqw class='tvwjwn'><jhd id='tvwjwn'></jhd></tlfqw></div> </body>

{"id":2521,"date":"2023-10-20T10:02:22","date_gmt":"2023-10-20T02:02:22","guid":{"rendered":"\/\/www.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/"},"modified":"2024-01-03T17:44:20","modified_gmt":"2024-01-03T09:44:20","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%9c%a82023-esmo%e5%b9%b4%e4%bc%9a%e5%b1%95%e7%a4%ba%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%9711%e9%a1%b9%e6%9c%80%e6%96%b0%e7%a0%94%e7%a9%b6%e6%88%90\/","title":{"rendered":"Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023"},"content":{"rendered":"\n

\u201cThis year\u2019s ESMO Congress highlighted the most recent results from 11 clinical studies conducted with our core product, toripalimab,\u201d said Dr. Jianjun ZOU, Global Research and Development President of Junshi Biosciences. \u201cAmong these studies, the results of EXTENTORCH study involving small cell lung cancer and the RENOTORCH study focusing on renal cell carcinoma were presented for the first time. As \u2018PD-1+X\u2019 combination therapy achieves further clinical advancement across multiple indications, it will further bolster Junshi Biosciences\u2019 extensive immuno-oncology pipeline, one that has been cultivated through many years of dedication.\u201d<\/p>\n\n\n\n

The RENOTORCH Study<\/strong>: Median PFS reaches 18.0 months! Record-setting results for 1^{st<\/sup> line immunotherapy in advanced kidney cancer<\/strong><\/p>\n\n\n\n}

Led by Professor Jun GUO of Beijing Cancer Hospital and Professor Yiran HUANG of Renji Hospital affiliated with Shanghai Jiao Tong University School of Medicine, RENOTORCH is China\u2019s first phase III clinical study to focus on immunotherapy for advanced renal cell carcinoma. Study findings were unveiled for the first time during a proffered paper session at the ESMO Congress. Professor Xinan SHENG of Beijing Cancer Hospital gave a comprehensive overview of the research results in the oral presentation. The full manuscript of the study has also been published in Annals of Oncology<\/em><\/a> (Impact factor 51.8) on the day of presentation.<\/p>\n\n\n\n

The RENOTORCH study (NCT04394975) is a randomized, open-label, multicenter phase III clinical study that enrolled 421 patients from 47 medical centers with intermediate to high-risk unresectable or metastatic renal cell carcinoma (RCC) who had received no prior systematic treatment. RENOTORCH is the first pivotal phase III study of immunotherapy for advanced RCC in China.<\/p>\n\n\n\n

As of March 31, 2023 (median follow-up time of 14.6 months), the RENOTORCH interim analysis results demonstrated that when compared to sunitinib monotherapy, toripalimab combined with axitinib significantly improved the patients\u2019 progression-free survival (PFS) and objective response rate (ORR) while maintaining a manageable safety profile.<\/p>\n\n\n\n

According to assessments by the independent review committee (IRC), the median PFS was 18.0 months in the toripalimab-axitinib group, nearly double that of the sunitinib group, which had a median PFS of 9.8 months. Toripalimab plus axitinib reduced the risk of disease progression or death by 35% (HR=0.65; 95% CI: 0.49-0.86; P=0.0028) compared to sunitinib. The 1-year and 2-year PFS rates of these two groups were 62.7% vs. 45.4% and 44.6% vs. 30.2%, respectively. Notably, unlike previous studies of a similar nature that included patients across all risk levels, this study only enrolled patients at intermediate to high risk and yet still achieved the longest median PFS ever reported in 1^{st<\/sup> line RCC.<\/p>\n\n\n\n}

When compared to patients in the sunitinib group, toripalimab-axitinib provided a superior ORR (IRC-assessed ORR of 56.7% vs. 30.8%, P<0.001) and a prolonged duration of response (DoR) (median DoR not yet reached vs. 16.7 months; HR=0.614; 95% CI: 0.340-1.137).<\/p>\n\n\n\n

At the interim analysis, an OS trend favoring the toripalimab plus axitinib combination over sunitinib monotherapy (median OS not yet reached vs. 26.8 months) has also been demonstrated, with a 39% lower risk of death (HR=0.61; 95% CI: 0.40-0.92). The 1-year and 2-year OS rates of the toripalimab-axitinib group and sunitinib group were 90.5% vs. 81.9% and 71.8% vs. 63.2%, respectively.<\/p>\n\n\n\n

The combination had a manageable safety profile and no new safety signals were identified.<\/p>\n\n\n\n

In July 2023, based on RENOTORCH\u2019s promising results, the National Medical Products Administration (NMPA) formally accepted the supplemental new drug application for toripalimab plus axitinib as the first-line treatment for patients with unresectable or metastatic RCC.<\/p>\n\n\n\n

The EXTENTORCH Study:<\/strong> World\u2019s 1^{st<\/sup> PD-1 inhibitor to achieve both positive PFS and OS results in phase III SCLC study<\/strong><\/p>\n\n\n\n}

EXTENTORCH, a phase III study of toripalimab combined with chemotherapy as first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), made its debut as a late-breaking abstract at the ESMO Congress 2023. The study was led by principal investigator Professor Ying CHENG of Jilin Cancer Hospital, and presented by Professor Ying LIU from Jilin Cancer Hospital at the ESMO Congress.<\/p>\n\n\n\n

The EXTENTORCH study (NCT04012606) is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study designed to compare the efficacy and safety of toripalimab vs. placebo in combination with etoposide plus platinum for the first-line treatment of ES-SCLC. EXTENTORCH enrolled a total of 442 ES-SCLC patients who had received no prior systematic treatment from 51 medical centers in China. In May 2023, EXTENTORCH successfully reached its primary endpoints, and toripalimab became the world\u2019s first PD-1 inhibitor to achieve two primary endpoints, OS and PFS, in a phase III study of first-line treatment for ES-SCLC.<\/p>\n\n\n\n

The findings from the EXTENTORCH study revealed that compared to chemotherapy alone, toripalimab plus chemotherapy for the first-line treatment of patients with ES-SCLC, coupled with toripalimab monotherapy as maintenance therapy, significantly prolonged PFS and OS while maintaining a manageable safety profile. With these promising results, toripalimab combined with chemotherapy is poised to become a standard first-line therapy for ES-SCLC. <\/p>\n\n\n\n

The final PFS analysis (median follow-up time of 11.8 months) demonstrated that compared to chemotherapy alone, toripalimab combined with chemotherapy significantly improved patients\u2019 PFS (researcher-assessed median PFS of 5.8 vs. 5.6 months) while reducing the risk of disease progression or death by 33% (HR=0.667; 95% CI: 0.539-0.824; P=0.0002).<\/p>\n\n\n\n

Biomarker analyses revealed that both PFS and OS improved in the toripalimab-chemotherapy group, regardless of the patients\u2019 tumor mutational burden (TMB) status. Additionally, mutations in focal adhesion\/integrin pathway were associated with poorer PFS and OS prognoses in patients receiving toripalimab plus chemotherapy.<\/p>\n\n\n\n

In terms of safety, toripalimab combined with chemotherapy has a manageable safety profile and no new safety signals were identified.<\/p>\n\n\n\n

In July 2023, based on the EXTENTORCH trial results, the NMPA accepted the supplemental new drug application for toripalimab plus etoposide and platinum as the first-line treatment of ES-SCLC.<\/p>\n\n\n","protected":false},"excerpt":{"rendered":"